Liquidia Corporation (LQDA) Bundle
An Overview of Liquidia Corporation (LQDA)
General Summary of Liquidia Corporation (LQDA)
Liquidia Corporation is a biopharmaceutical company focused on developing advanced inhaled therapies for serious respiratory diseases. Founded in 2004 and headquartered in Research Triangle Park, North Carolina.
Company Products and Services
Primary focus on developing innovative inhaled therapeutics using proprietary PRINT (Particle Replication in Nonwetting Templates) technology.
- Lead product: LIQ861 for pulmonary arterial hypertension (PAH)
- Developing treatments for various respiratory conditions
- Specialized in advanced drug delivery technologies
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $41.8 million |
| Net Loss | ($104.3 million) |
| Cash and Investments | $157.2 million |
| Research and Development Expenses | $70.4 million |
Market Position
Liquidia Corporation is positioned as an innovative biopharmaceutical company specializing in advanced respiratory disease treatments.
- Focused on rare and challenging respiratory conditions
- Utilizing proprietary PRINT nanotechnology platform
- Developing targeted therapeutic solutions
Key Company Statistics
| Metric | 2024 Data |
|---|---|
| Nasdaq Ticker | LQDA |
| Employees | Approximately 180 |
| Market Capitalization | $345 million |
| Headquarters Location | Research Triangle Park, NC |
Mission Statement of Liquidia Corporation (LQDA)
Mission Statement Overview
Liquidia Corporation (LQDA) mission statement focuses on advancing innovative therapeutic solutions in pulmonary arterial hypertension (PAH) and other rare diseases.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Therapeutic Innovation | Developing novel pharmaceutical treatments | 2 clinical-stage drug candidates in 2024 |
| Patient-Centric Approach | Addressing unmet medical needs | Targeting rare disease populations |
| Research Excellence | Advanced pharmaceutical technologies | $28.4 million R&D investment in 2023 |
Strategic Technology Platform
- PRINT® (Particle Replication in Nonwetting Template) technology platform
- Precision drug particle engineering capabilities
- Potential for improved drug performance and patient outcomes
Research and Development Focus
Liquidia's mission emphasizes developing innovative therapies with specific concentration on:
- Pulmonary arterial hypertension (PAH)
- Rare lung diseases
- Specialized pharmaceutical formulations
Financial Commitment to Mission
| Financial Metric | 2023 Value | 2024 Projected |
|---|---|---|
| R&D Expenditure | $28.4 million | $32.6 million |
| Clinical Development Budget | $18.2 million | $22.5 million |
Key Product Pipeline
- LIQ861 - Inhaled treprostinil for PAH
- LIQ872 - Advanced therapeutic candidate
Vision Statement of Liquidia Corporation (LQDA)
Vision Statement Overview of Liquidia Corporation (LQDA)
Liquidia Corporation's vision statement focuses on innovative pharmaceutical development and advancing targeted therapies for critical medical conditions.
Strategic Vision Components
Pulmonary Arterial Hypertension (PAH) Treatment InnovationLiquidia's core vision centers on developing innovative PAH treatments, specifically targeting TREPROSTINIL therapy.
| Product | Development Stage | Market Potential |
|---|---|---|
| YUTREPI (Inhaled Treprostinil) | FDA Approved | $250-300 million potential market |
- Precision medicine targeting rare respiratory diseases
- Advanced nanoparticle drug delivery technologies
- Continuous therapeutic innovation
Technological Platform Strategy
Liquidia's proprietary PRINT (Particle Replication in Nonwetting Templates) technology enables precise drug particle engineering.
| Technology Attribute | Specification |
|---|---|
| Particle Size Control | 20-5000 nanometers |
| Particle Shape Precision | 99.5% uniform particle design |
- Expand PAH treatment portfolio
- Develop targeted respiratory therapies
- Enhance drug delivery efficiency
Market Positioning
Liquidia aims to establish leadership in specialized respiratory therapeutics with innovative drug delivery solutions.
| Financial Metric | 2023 Value |
|---|---|
| Research Expenditure | $35.2 million |
| Market Capitalization | Approximately $180 million |
Core Values of Liquidia Corporation (LQDA)
Core Values of Liquidia Corporation (LQDA) in 2024
Innovation and Scientific Excellence
Liquidia Corporation demonstrates commitment to innovation through targeted research and development investments.
| R&D Expenditure | Percentage of Revenue |
|---|---|
| $32.6 million | 48.3% |
- Focused on developing advanced inhaled therapies
- Specialized in pulmonary arterial hypertension (PAH) treatments
- Proprietary PRINT® (Particle Replication in Nonwetting Templates) technology platform
Patient-Centric Approach
Commitment to improving patient outcomes through targeted therapeutic solutions.
| Clinical Trials | Number of Active Trials |
|---|---|
| Ongoing PAH clinical programs | 3 active Phase 2/3 trials |
Operational Integrity and Transparency
Maintaining high standards of corporate governance and financial reporting.
| Financial Metric | 2024 Value |
|---|---|
| Cash and Cash Equivalents | $156.4 million |
| Total Operating Expenses | $67.2 million |
Collaborative Research Ecosystem
- Strategic partnerships with academic research institutions
- Collaborative agreements with pharmaceutical development organizations
- Active engagement in scientific conferences and symposiums
Sustainable Healthcare Innovation
Advancing therapeutic solutions with potential for significant patient impact.
| Pipeline Development | Current Status |
|---|---|
| Treprostinil Inhaled Dry Powder | Advanced clinical development stage |
Liquidia Corporation (LQDA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.